Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Royce & Associates LP

Royce & Associates LP lowered its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 17.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,004,501 shares of the medical technology company’s stock after selling 207,785 shares during the quarter. Royce & Associates LP owned 0.71% of Alphatec worth $9,221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. R Squared Ltd acquired a new stake in Alphatec in the 4th quarter valued at about $29,000. Nisa Investment Advisors LLC raised its holdings in Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 4,234 shares in the last quarter. Newton One Investments LLC purchased a new position in Alphatec in the fourth quarter worth approximately $50,000. AlphaQuest LLC acquired a new position in Alphatec during the 4th quarter worth approximately $80,000. Finally, Oppenheimer Asset Management Inc. purchased a new stake in shares of Alphatec in the 4th quarter valued at approximately $106,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Stock Down 4.2 %

Shares of NASDAQ:ATEC opened at $9.34 on Wednesday. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $14.88. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The stock has a market cap of $1.35 billion, a P/E ratio of -7.30 and a beta of 1.39. The firm has a fifty day moving average price of $10.95 and a 200 day moving average price of $8.80.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling at Alphatec

In other news, EVP David Sponsel sold 12,946 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $10.73, for a total value of $138,910.58. Following the completion of the sale, the executive vice president now owns 722,128 shares in the company, valued at approximately $7,748,433.44. This trade represents a 1.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This trade represents a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 337,321 shares of company stock worth $3,828,060. 22.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Barclays boosted their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Alphatec in a research report on Thursday, February 27th. Piper Sandler increased their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Finally, StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.